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Abstract
BACKGROUND: Studies on the effect of comorbidities on breast cancer operation have been limited
and inconsistent. This study investigated whether pre-existing comorbidities influenced breast cancer
surgical operation in an equal access health care system.
METHODS: This study was based on linked Department of Defense cancer registry and medical
claims data. The study subjects were patients diagnosed with stage I to III breast cancer during
2001 to 2007. Logistic regression was used to determine if comorbidity was associated with operation
type and time between diagnosis and operation.
RESULTS: Breast cancer patients with comorbidities were more likely to receive mastectomy (odds
ratio [OR] 5 1.27; 95% confidence interval [CI], 1.14 to 1.42) than breast conserving surgery plus radiation. Patients with comorbidities were also more likely to delay having operation than those without
comorbidities (OR 5 1.27; 95% CI, 1.14 to 1.41).
CONCLUSIONS: In an equal access health care system, comorbidity was associated with having a
mastectomy and with a delay in undergoing operation.
Ó 2013 Elsevier Inc. All rights reserved.

The authors declare no conflicts of interest.
This project was supported by John P. Murtha Cancer Center, Walter Reed National Military Medical Center via the Uniformed Services University of the
Health Sciences under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine and by the intramural research program
of the National Cancer Institute. The original data linkage was supported by the former United States Military Cancer Institute (USMCI) and Division of
Cancer Epidemiology and Genetics (DCEG), National Cancer Institute. The views expressed in this article are those of the author and do not necessarily
reflect the official policy or position of the Department of the Navy, Army, Department of Defense, National Cancer Institute, or the U.S. Government. Nothing in the presentation implies any federal/DOD/DON endorsement.
* Corresponding author. Division of Military Epidemiology and Population Sciences, John P. Murtha Cancer Center, Walter Reed National Military
Medical Center, 11300 Rockville Pike, Suite 1215, Rockville, MD 20852. Tel.: 11 301 816 4786; fax: 11 301 881 7197.
E-mail address: kangmin.zhu@usuhs.edu
Manuscript received April 27, 2012; revised manuscript December 15, 2012
0002-9610/$ - see front matter Ó 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.amjsurg.2013.01.034

This article is a U.S. government work, and is not subject to copyright in the United States.

394

The American Journal of Surgery, Vol 206, No 3, September 2013

Breast cancer is the most common occurring cancer and the
second leading cause of cancer mortality among US women.1
In 2012, it was estimated that 226,870 new breast cancer cases
would be diagnosed with 39,510 deaths due to breast cancer.1
Effective treatment reduces the mortality of the disease.2 The
local treatment for nonmetastatic breast cancer is either mastectomy or breast conserving surgery (BCS) followed by radiation.3 Various factors can influence whether women receive
BCS or mastectomy.4,5 Comorbidity, the coexistence of
chronic diseases or acute illnesses in addition to the index disease, may influence the selection and timing of treatment.
Studies of the effect of comorbidities on treatment decisions
have been limited and inconsistent. Several studies have shown
that comorbidities present at the time of cancer diagnosis
influence treatment choice.6–10 For example, Mandelblatt et al9
found that women with high levels of comorbidity were
more likely to receive a mastectomy (odds ratio [OR] 5
3.33; 95% confidence interval [CI], 1.23 to 9.00) or BCS alone
(OR 5 16.6; 95% CI, 4.87 to 56.5) than BCS and radiation
compared with women who have low levels of comorbidity.
Thompson et al10 also reported that the likelihood of having
a mastectomy was higher among women who had anemia
or heart failure. On the other hand, an association between
comorbidities and cancer therapy was not identified in other
studies.11,12 Furthermore, few studies have assessed whether
comorbidities are associated with delayed breast cancer operation,13,14 although the presence of comorbidities was shown
to increase the waiting time for breast cancer operation.13
Many previous studies were based on cancer patients with
medical insurance.13,15,16 People with certain pre-existing
conditions and with low socioeconomic status, however,
may not be able to obtain insurance and thus were not included in these studies. Due to the selectiveness, the study
participants might differ from those excluded based on
pre-existing conditions and low socioeconomic status. Therefore, study results on comorbidities might have been affected.
The Department of Defense (DoD) military health care
system provides universal medical care to its beneficiaries,
including active duty members, retirees, and their family
members. Because there are no financial incentives to physicians and cost prohibitions for patients within the system, a
study based on this system provides a unique opportunity to
identify factors that may influence treatment decisions while
minimizing the effects of socioeconomic factors. The objective
of this study was to investigate whether pre-existing comorbidities were associated with the selection of initial breast
cancer surgical operation, using linked DoD cancer registry and
medical claims data. In addition, the study assessed whether
comorbidities were associated with delayed surgical operation.

Methods
Data sources and study subjects
This study was based on linked data from the DoD
Central Cancer Registry (CCR) and the Military Health

System Data Repository (MDR). The CCR was initiated in
1998 and contains tumor-specific (eg, site, histology, stage,
and treatment) and person-specific (eg, sex, race, and age at
diagnosis) information on those diagnosed or treated at
military treatment facilities. The MDR includes administrative and medical claims’ information for all DoD beneficiaries, including information on clinical diagnoses, diagnostic
procedures, treatments including operation type, medical
conditions including comorbidities, prescription medications, and related costs. The data linkage was approved by
the National Naval Medical Center institutional review board
(IRB), the Armed Forces Institute of Pathology IRB, the
National Cancer Institute IRB, and TRICARE Management
Activity, which manages the DoD’s health care program.
The subjects eligible for this study were 5,548 female
breast cancer patients with histologically confirmed, first
primary malignant breast tumors diagnosed from 2001 to
2007. Only patients with stages I to III, defined by the
American Joint Committee on Cancer staging system,17
were included because surgical operation often applies to
them as a therapeutic procedure. There was only 1 woman
diagnosed during the study period who had missing operation information and she was, therefore, excluded from the
study.

Measures
Extensive procedures were undertaken to evaluate and
consolidate the data from the CCR and MDR. Data on
operation type, radiation therapy, and chemotherapy were
obtained from both the CCR and MDR. In the CCR,
Registry Operations and Data Standards (ROADS) or
Facility Oncology Registry Data Standards (FORDS) codes
were used to identify the type of operation performed.18 In
the MDR, both the International Classification of Diseases
9th revision (ICD-9) codes and the Current Procedural Terminology (CPT) codes were used to identify whether patients underwent BCS or mastectomies (including
subcutaneous mastectomies, simple mastectomies, radical
mastectomies, and modified radical mastectomies). Radiation therapy and chemotherapy were categorized as yes or
no according to the documentation in both the CCR and
MDR. Hormonal therapy information was obtained only
from the CCR because MDR prescription data were not
available for the entire study period. Demographic (age at
diagnosis, race, marital status, duty status) and tumor
(stage, grade, size, and estrogen receptor [ER] status) variables were obtained from the CCR.
Data on the existence of comorbidities were extracted
from the MDR using ICD-9 codes. To assess the level of
comorbidities, we computed the modified Charlson comorbidity index,19 which consists of 17 comorbid conditions
including cancer; breast cancer was excluded from the calculation. Comorbidities were considered to be present if a
diagnosis was recorded during the 1 year prior to surgical
operation either 1 time in inpatient data or 3 times in
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outpatient data. The comorbid conditions present were classified as Charlson index 5 0 or Charlson index R1. The 2
most common comorbidities were chronic obstructive pulmonary disease and diabetes (data not shown). There was a
relatively small proportion of women with a Charlson index
R1 (n 5 473); therefore, further classification of comorbidity level was not explored.

Statistical analysis
The distributions of basic characteristics for those with
and without comorbidities were compared using Chi-square
tests. The odds ratios and 95% confidence intervals were
calculated using multinomial logistic regression to compare
the probability of receiving different surgical operations
while adjusting for age, race, marital status, military duty
status, year of diagnosis, tumor stage, tumor grade, tumor
size, estrogen receptor (ER) status, chemotherapy, and
hormonal therapy. Treatment selection may vary by tumor
and demographic features; therefore, models were then
stratified by age, race, marital status, duty status, tumor
stage, tumor grade, tumor size, and ER status. The impact
of comorbidities on the interval between cancer diagnosis
and surgical operation was also examined. Time interval
was dichotomized as %2 months vs .2 months following
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breast cancer diagnosis. Analyses were conducted using
SAS software (version 9.1; SAS, Cary, NC).

Results
The distributions of selected demographic, diagnostic,
and treatment factors by comorbidity status are shown in
Table 1. Compared with women without comorbidities,
women with at least 1 comorbidity were more likely to
be older, not married, non-active duty military, have later
stage tumors, and less likely to have received chemotherapy. The distribution of race between the 2 groups was
not significantly different. There were also no significant
differences in year of diagnosis, tumor grade, tumor size,
ER status, and receipt of hormonal therapy between those
with and without comorbidities (data not shown).
A comparison of treatment by comorbidity is shown in
Table 2. In comparison to patients without comorbidities,
patients with comorbidities were more likely to have received a mastectomy (OR 5 1.27; 95% CI, 1.14 to 1.42)
or mastectomy plus radiation (OR 5 1.16; 95% CI, 1.00
to 1.35) than BCS plus radiation. However, patients with
comorbid conditions were as likely to have BCS alone as
BCS plus radiation (OR 5 .96; 95% CI, .74 to 1.23) compared with those without comorbidities. Receipt of radiation did not seem to affect the association between

Table 1 Distributions of demographic, diagnostic, and treatment factors by comorbidity status among female Department of Defense
beneficiaries diagnosed with breast cancer between 2001 and 2007 (N 5 5,548)
Comorbidity
Charlson index 5 0
Factor
Age at Diagnosis
,50
R50
Race
White
Black
Other†
Unknown
Marital Status
Single/separated/divorced/widowed
Married
Unknown
Duty Status at Diagnosis
Active duty
Non-active duty
Tumor Stage
Stage I
Stage II
Stage III
Chemotherapy
Yes
No

Charlson index R 1

N

%

N

%

P value*

1,914
3,161

38
62

78
395

16
84

,.01

3,596
799
531
149

71
16
10
3

339
68
59
7

72
14
12
1

.14

867
4,078
130

17
80
3

123
344
6

26
73
1

,.01

289
4,786

6
94

16
457

3
97

.03

2,570
1,938
567

51
38
11

214
189
70

45
40
15

.02

2,882
2,193

57
43

218
255

46
54

,.01

*Chi-square test.
†
American Indian, Aleutian, Eskimo, Asian, or Pacific Islander.
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Table 2 Multinomial logistic regression analyses assessing the likelihood of operation type among female Department of Defense
beneficiaries with breast cancer, 2001 to 2007 (N 5 5,548)
Comorbidity
Charlson index 5 0

Charlson index R 1

Surgical operation

N

%

N

%

OR (95% CI)*

BCS 1 radiation
BCS only
Mastectomy 1 radiation
Mastectomy only

2,369
254
1,003
1,449

47
5
20
29

169
20
101
183

36
4
21
39

Reference
.96 (.74–1.23)
1.16 (1.00–1.35)†
1.27 (1.14–1.42)†

BCS 5 breast conserving surgery; CI 5 confidence interval; OR 5 odds ratio.
* All models were adjusted for age at diagnosis, race, marital status, duty status at diagnosis, year of diagnosis, tumor stage, tumor grade, tumor size,
estrogen receptor status, chemotherapy, and hormonal therapy.
†
P , .05.

comorbidity and type of operation; therefore, only operation type was considered in further stratified analyses.
Stratified analyses indicated that the association between
comorbidity and operation type varied by tumor stage and
size (Table 3); significant associations were observed
among women with stage II tumors and tumors .2 cm,
but not among women with stage I tumors or tumors %2
cm. The association was close to the statistical significance
level for women with stage III tumors. Women with comorbidities were more likely to receive mastectomy than BCS
regardless of their marital and ER statuses (data not
shown). Additionally, although the statistical significance
of an association between comorbidity and operation type
seemed to vary when stratified by age at diagnosis, race,
duty status, and tumor grade, the strata-specific confidence

intervals overlapped, making it less clear whether the association truly differed across these covariate categories (data
not shown).
Table 4 shows the relationship between comorbidity and
the time interval from cancer diagnosis to surgical operation. The majority of the operations were performed within
2 months of cancer diagnosis (81% for those without comorbidities and 70% for those with comorbidities). However, patients with comorbidities were more likely to
have delayed surgical operation (OR 5 1.27; 95% CI,
1.14 to 1.41) than patients without comorbidities. When
stratified by operation type, the results indicated that comorbidity was significantly associated with delayed operation for both BCS (OR 5 1.26; 95% CI, 1.07 to 1.50) and
mastectomy (OR 5 1.26; 95% CI, 1.11 to 1.47).

Table 3 Stratified multinomial logistic regression analyses assessing the likelihood of operation type among female Department of
Defense beneficiaries with breast cancer, 2001 to 2007 (N 5 5,548)
Comorbidity
Stratum
Tumor Stage
Stage I
Stage II
Stage III
Tumor Size (cm)†
%2
.2

Charlson index 5 0

Charlson index R 1

Surgical operation

N

%

N

%

OR (95% CI)*

BCS
Mastectomy
BCS
Mastectomy
BCS
Mastectomy

1,612
958
894
1,044
117
450

63
37
46
54
21
79

122
92
59
130
8
62

57
43
31
69
11
89

Reference
.90 (.72–1.14)
Reference
1.39 (1.15–1.69)‡
Reference
1.45 (.98–2.16)

BCS
Mastectomy
BCS
Mastectomy

2,336
1,897
251
476

55
45
35
65

175
208
9
66

46
54
12
88

Reference
1.10 (.95–1.27)
Reference
1.96 (1.32–2.91)‡

BCS 5 breast conserving surgery; CI 5 confidence interval; OR 5 odds ratio.
*Unless stratified by the variable, all models were adjusted for radiation, age at diagnosis, race, marital status, duty status at diagnosis, year of
diagnosis, tumor stage, tumor grade, tumor size, estrogen receptor status, chemotherapy, and hormonal therapy.
†
Unknown categories are not included; therefore, values for tumor size do not add up to total number of patients.
‡
P , .05.
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Comments
Comorbidity may complicate the selection of surgical
operation for breast cancer because these conditions likely
affect treatment tolerance and patient survival. The results
of this study indicate that breast cancer patients with
comorbidities were less likely to receive BCS plus radiation
and more likely to receive mastectomy. Stratified analyses
indicated that this association existed regardless of marital
and ER statuses but could vary by tumor stage and size.
Comorbidity was also significantly associated with delayed
operation for both BCS and mastectomy.
The primary treatment of non-metastatic breast cancer
has changed dramatically during the past 2 decades. The
National Institutes of Health Consensus Development
Conference established BCS with radiation as an appropriate primary therapy for women with non-metastatic breast
cancer in 1990.20 Randomized trials have also shown that
BCS with radiation was as effective as mastectomy in treating breast cancer,21–24 while body image of patients treated
with BCS seems to be better.25 Thus, BCS has replaced
mastectomy as the most common procedure for the treatment of breast cancer without metastasis.26–28 However,
the optimal treatment for patients with comorbidity is still
uncertain because patients with pre-existing serious diseases were generally not eligible for those trials.29
Although this study suggests that women with comorbidities are more likely to undergo mastectomy than BCS, the
underlying reasons for this choice are not clear. Indeed, these
findings are somewhat paradoxical, because mastectomy is a
more time-consuming operation with higher complication
rates and morbidity than BCS,30 and one might expect that
women with comorbidities would choose the least invasive
procedure (BCS). It is likely that patients with comorbidities
and their doctors may choose mastectomy over BCS to avoid
the possibility of a 2nd operation (usually mastectomy) if
cancer recurs.31 Patients with comorbidities and their
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physicians may also choose mastectomy to avoid the need
for radiotherapy because it has been associated with lifethreatening conditions, including vascular disease (although
radiotherapy may now also be recommended after mastectomy for patients with node-positive or large tumors).32–35
On the other hand, in comparison to women with comorbidities, women without comorbidities may be more likely to
receive neoadjuvant chemotherapy before local treatment
to reduce the size of the tumor, which in turn may make
them more likely to undergo the less invasive BCS.36 However, the low frequencies of chemotherapy prior to surgical
operation in this study’s data suggest that this might not be
a main reason for the identified association (data not shown).
Research has also shown that undergoing mastectomy is associated with greater patient involvement in the treatment
decision-making process.37 However, whether patients with
comorbidities are more likely to be involved in making their
treatment decisions is unknown.
Our stratified analysis showed an association between
comorbidities and operation type among patients with
stage II or large (.2 cm) tumors, but not those with stage I
or small (%2 cm) tumors. It is not clear why the
association between operation type and comorbidity
would vary by tumor stage or size. As stated above,
patients with comorbidities and their doctors may choose
mastectomy over BCS to avoid the possibility of a 2nd
operation or radiation therapy. This possibility may make
it more sensible for patients with larger, advanced stage
tumors that are more likely to recur38 to receive the more
aggressive mastectomy.
In agreement with our studies, Simunovic et al13 reported that comorbidities were associated with longer delays for breast cancer surgical operation in Ontario,
Canada. The treatment decisions for patients with comorbidities are likely more complicated than those without,
and physicians may need more time to evaluate patients’
health status and make decisions, which may result in

Table 4 Multinomial logistic regression analyses assessing the effects of comorbidity on the interval between breast cancer diagnosis
and surgical operation among female Department of Defense beneficiaries, 2001 to 2007
Comorbidity
Surgical operation
Any
BCS
Mastectomy

Time interval*
‡

Within 2 months
More than 2 months
Within 2 months‡
More than 2 months
Within 2 months‡
More than 2 months

Charlson index 5 0

Charlson index R 1

N

%

N

%

OR (95% CI)†

4,098
976
2,164
458
1,934
518

81
19
83
18
79
21

332
141
138
51
194
90

70
30
73
27
68
32

Reference
1.27 (1.14–1.41)x
Reference
1.26 (1.07–1.50)x
Reference
1.26 (1.11–1.47)x

BCS 5 breast conserving surgery; CI 5 confidence interval; OR 5 odds ratio.
*One patient with missing time interval information was not included in this analysis.
†
Adjusted for radiation, age at diagnosis, race, marital status, duty status at diagnosis, year of diagnosis, tumor stage, tumor grade, tumor size,
estrogen receptor status, chemotherapy, and hormonal therapy.
‡
Initial breast surgery performed within 1–2 month of the breast cancer diagnosis.
x
P , .05.
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longer waiting time before surgical operations for patients
with comorbidities.
There are several potential limitations to this study.
First, information from administrative claims’ data may be
incomplete or inaccurate. For example, the comorbid
conditions from the outpatient data might not be accurate.
However, we tried to minimize the inaccuracies by
requiring 3 outpatient occurrences of a diagnostic code
instead of 1. Given that the stricter criterion was applied,
we cannot exclude the possibility that comorbidity was
underestimated. However, this might only dilute the true
differences between those with and without comorbidity
in receiving different surgical operations. Second, some
patients, especially military dependants and retirees,
might have other medical insurance; therefore, some
information about their treatment and medical conditions
might not have been included. Third, according to the
IRB-approved procedures, the data contained only month
and year of cancer diagnosis or operation and not the exact
date. Therefore, some patients with an operation performed .2 months after diagnosis might have had it
within 1 to 2 months following the diagnosis. However,
this misclassification would tend to underestimate, rather
than overestimate, the true association of the time interval
between diagnosis and mastectomy. Finally, as there were
relatively small numbers of patients with comorbidities,
we were not able to evaluate the impact of the severity of
the pre-existing comorbidity or specific comorbid conditions on the treatment choice of breast cancer patients.
Although BCS is generally regarded as the preferred
surgical operation for primary breast cancer, it may not be
as accepted for patients with certain comorbidities. The
results of our study highlight the need to establish treatment
standards for patients with pre-existing conditions. It is not
known whether patients’ perceptions of their physicians’
treatment preferences and patient–provider communication
contribute to the choice of treatment.39,40 Treatment standards for patients with comorbidities should guide physicians’ recommendations and discussions with patients.
Patients with comorbidities should be fully informed about
the possible treatment choices, thus allowing them to make
informed decisions.41 Also, comorbidities appear to be associated with surgical operation delay, and this needs to be
further studied because it could adversely affect long-term
outcomes.
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